The United States gave the green light to a new Moderna COVID-19 vaccine late Friday, but it comes with restrictions on eligible users. This does not replace the company’s current shot; instead, it serves as an additional option.
This new vaccine, known as mNexspike, represents progress towards next-gen coronavirus vaccines. It’s engineered in a way that requires only a fifth of the dose of Moderna’s existing COVID-19 vaccine, Spikevax, by honing its immune target.
Stephane Bancel, the CEO of Moderna, stated on Saturday that the approval “provides an important new tool to aid in safeguarding individuals at a high risk of severe illness from COVID-19.”
The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus.
That’s the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax.
Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials.
Moderna’s existing vaccine doesn’t face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall.
The FDA’s approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna’s existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said.
The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Copyright 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
